The Voss Report — June 14, 2026

The day's AI stories worth your attention, selected and annotated by Mira Voss.

[SpaceX stock soars 20% on debut, making Musk world's first trillionaire](https://www.nytimes.com/2026/06/12/technology/spacex-ipo-elon-musk.html) The New York Times The IPO priced at $135, opened at $150, and closed above $160 — the largest offering in history. What the S-1 calls a unified "space, connectivity, and AI" business is three very different financial profiles bundled without a clean valuation separation. Morningstar puts fair value at $63. The distance between $63 and $160 is mostly a question about xAI that the document is designed not to answer.

[Amazon security research reportedly triggered the White House's Anthropic Fable ban](https://www.theverge.com/ai-artificial-intelligence/949601/amazon-anthropic-fablemythos-government-ban) The Verge The export control directive that cut off access to Fable 5 and Mythos 5 was triggered in part by Amazon's own cybersecurity research flagging capability concerns — the lab's primary cloud infrastructure partner helped build the case for restricting its own product. The full chain from lab to AWS to White House to export ban has not been reported; what's confirmed is that the infrastructure relationship flows in both directions.

[70% of US working-age adults still don't regularly use AI — and Gen Z adoption has stalled](https://gabrielweinberg.com/p/people-are-consuming-ai-like-they) Gabriel Weinberg / Gallup / Microsoft Gallup year-over-year data shows Gen Z AI adoption all but flat (81% use it at least rarely, but the "rarely" category is doing most of the work), while Microsoft's telemetry-based US AI Diffusion report puts regular AI usage at under 30% of working-age adults. The industry's narrative about ubiquitous, compounding adoption is running well ahead of what the numbers support.

[Anthropic reports early Claude chemistry benchmarks: NMR prediction, structure elucidation](https://flipso.com/p/i6d8vw308) Reuters Anthropic published early results on adapting Claude for NMR prediction and molecular structure elucidation — the first substantive claim of meaningful performance on scientific instrument analysis. This matters because biosecurity regulatory frameworks largely assumed AI lacked this capability; those assumptions are now worth reviewing.

[What the SpaceX IPO means for the OpenAI and Anthropic IPO pipelines](https://www.nytimes.com/2026/06/12/technology/spacex-ipo-openai-anthropic.html) The New York Times Strong investor appetite for SpaceX at 2–3x analyst fair value is being read as a proof of concept for the OpenAI and Anthropic offerings already signaled for later this year. The capital market thesis — that AI companies trade on potential rather than demonstrated unit economics — is getting its first live test at scale. The SpaceX S-1 is, in this reading, a template as much as a document.

The Voss Report runs daily. For original reporting, see The Signal, The Mirror, and The Becoming.